[Non-hematologic toxicity in high-dose cytarabine therapy].
The hence reported non-haematologic toxicity in high-dose cytarabin mainly concerned CNS (cerebellar dysfunction), eyes (keratitis and conjunctivitis), skin (erythema), and gastrointestinal tract (vomiting, diarrhea). It partly depends on dosage and partly on duration of treatment. A dose of 48 g/sq m within one cycle apparently represents a critical upper limit as hence especially the risk of irreversible brain damage increases. Considering the fact that the indication for high-dose cytarabin is given mainly for poor prognostic failures and relapses in acute leukemias toxicity seems to be acceptable.
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001927:Brain Diseases / Q000139:chemically induced; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007634:Keratitis / Q000139:chemically induced; D007938:Leukemia / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine
Nicht-hämatologische Toxizität bei der hochdosierten Cytarabin-Therapie.